Evidence map›Paper›PMID 41256404›Full record

ArticlebioRxiv : the preprint server for biology2025

Translocation of HIV capsid core through the Nuclear Pore Complex by affinity gradient.

Ivo Melčák, Ryan L Slack, Zachary C Lorson, Andres Emanuelli Castaner, Krisztina Ambrus, Jonathan S Winkjer, Karen A Kirby, Robert A Dick, Stefan G Sarafianos

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Ivo MelčákCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine; Atlanta, GA 30322, USA.ORCID 0009-0005-4787-1019
Ryan L SlackCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine; Atlanta, GA 30322, USA.ORCID 0000-0002-5928-6205
Zachary C LorsonCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine; Atlanta, GA 30322, USA.ORCID 0009-0002-1404-9086
Andres Emanuelli CastanerCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine; Atlanta, GA 30322, USA.ORCID 0009-0005-1275-9684
Krisztina AmbrusCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine; Atlanta, GA 30322, USA.ORCID 0009-0001-9891-3152
Jonathan S WinkjerCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine; Atlanta, GA 30322, USA.ORCID 0000-0002-9124-8372
Karen A KirbyCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine; Atlanta, GA 30322, USA.ORCID 0000-0003-2468-4796
Robert A DickCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine; Atlanta, GA 30322, USA.ORCID 0000-0003-3693-2531
Stefan G SarafianosCenter for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine; Atlanta, GA 30322, USA.ORCID 0000-0002-5840-154X

Funding

Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
X-ray Scattering Technology CoreP30GM133893 · NIGMS · BROOKHAVEN SCIENCE ASSOC-BROOKHAVEN LAB · PI Vivian Stojanoff · 2019 to 2026
$38.6M
Structural Biology CoreU54AI170855 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI Bruce Edward Torbett · 2022 to 2026
$36.7M
Structural studies of HIV Capsid with host factors and Capsid-targeting antiviralsR01AI120860 · NIAID · UNIVERSITY OF MISSOURI-COLUMBIA · PI Stefan G Sarafianos, Zhengqiang Wang · 2015 to 2026
$6.0M
Emory Training Program in Translational Research to End the HIV EpidemicT32AI157855 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2021 to 2026
$2.8M
Affinity Gradient-Based Transport of HIV Capsid Cores through the Nuclear Pore ComplexR21AI176946 · NIAID · EMORY UNIVERSITY · PI MELCAK, IVO, SARAFIANOS, STEFAN G · 2023 to 2024
$430k
NIAID NIH HHS P30 AI050409NIAID NIH HHS R01 AI120860NIAID NIH HHS R21 AI176946NIAID NIH HHS T32 AI157855NIAID NIH HHS U54 AI170855NIGMS NIH HHS P30 GM133893
6 · The paper itself

Abstract

The HIV capsid core encapsulates the viral genome for subsequent integration into host cellular DNA. Prior to nuclear entry, the core must translocate through the Nuclear Pore Complex (NPC). This transit involves interactions between the capsid core and phenylalanine-glycine (FG) repeats found in nucleoporins within the NPC. Despite this critical role in the viral replication cycle, the molecular mechanism of capsid core translocation remains unclear. FG repeats consist of three classes of canonical motifs: FG, GLFG, and FxFG motifs. These are segregated within the NPC to define distinct zones of the gating machinery. FG- and FxFG-type motifs are enriched in the cytoplasmic and nuclear ("nuclear basket") peripheries of the NPC while GLFG motifs are enriched in regions adjacent to the core of the NPC. To investigate the capsid core translocation, we use biochemical, biophysical, and structural approaches to study FG-capsid interactions in a quantitative manner. We show that the capsid (CA) interacts with a range of diverse FG repeats with varying affinities. GLFG motifs of core NUP98 exhibit increased affinity to CA proteins compared to other conventional FG/FxFG. However, the non-canonical FxFG motif of NUP153 at the "nuclear basket" significantly increases binding affinity to CA compared to canonical FxFG, therefore called FG super-motif. In addition, C-terminal motif of NUP153 consists of a stretch of basic residues, which enhances the affinity of this non-canonical FG super-motif to capsid core at the NPC nuclear periphery. We identified other binding enhancers of the NPC core FG-NUPs, NUP58 and POM121. The relationship between the binding strength of FG/FxFG binding enhancers of NUP58, POM121, NUP153 and their position within the NPC also shows capsid core binding affinity increases with increasing proximity to the "nuclear basket." Based on our data, the difference in binding affinities between the canonical FxFG motif and the enhancer-coupled FG super-motif of NUP153 to capsid cores at the "nuclear basket" is approximately 1,000-fold. Therefore, the diverse FG motifs and binding enhancers, which are naturally distributed within the NPC into distinct zones, create an avidity gradient-with changes in both concentration and binding affinity-along the cytoplasmic-nuclear axis. We suggest that HIV capsid translocation into the nucleus is potentiated by this gradient in a unidirectional manner (outside-to-inside) within the NPC.

Identifiers

PMID41256404
PMCPMC12621894

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.